IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
announced the publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22 in San Diego, California. The presentations will highlight preclinical data from three potential first-in-class programs from IDEAYA's clinical stage pipeline: IDE034, a PTK7/B7H3 bi-specific topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7; and IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently conducting Phase 1 clinical studies to evaluate safety, tolerability, PK and efficacy of these three programs across a broad range of large solid tumor indications, including lung, colorectal, pancreatic, breast, and prostate cancer. (PRNewsfoto/IDEAYA Biosciences, Inc.) "We are excited for the opportunity to showcase data from our earlier stage clinical pipeline at this year's AACR. These programs align closely with our cli
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline ProgramsPR Newswire
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline UpdatePR Newswire
- IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]Yahoo! Finance
- Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 [Yahoo! Finance]Yahoo! Finance
IDYA
Earnings
- 2/17/26 - Beat
IDYA
Sec Filings
- 3/2/26 - Form 4
- 2/17/26 - Form S-8
- 2/17/26 - Form SCHEDULE
- IDYA's page on the SEC website